Literature DB >> 18560950

[Surgical treatment options in oropharyngeal cancer].

Herwig Swoboda1.   

Abstract

Therapy of oropharyngeal squamous cell cancer traditionally has been radiation-based, with surgery mainly in reserve. With increasing depth of local infiltration and volume of regional metastases the role of surgery in safeguarding curative chances increases. However, after failed chemoradiation of oropharynx cancer, few patients are cured by salvage surgery. Thus, primary surgery with postoperative radiotherapy may be contemplated if circumtances are favorable. The oropharynx can be approached by transoral, transmandibular or transcervical routes. Primary surgery is increasingly valuable when resultant morbidity is decreased as in the case of more elaborated transoral approaches. Classical approaches also have improved with increasing use of midline mandibulotomy, marginal mandibulectomy, reconstructive surgery, selective neck dissection (ND), and rehabilitation. Elective ND is restricted to levels I or II to III or IV, therapeutic ND is comprehensive (classic or modified radical depending on capsular integrity), and salvage ND is individualized. Surgery, most often followed by radiotherapy, in selected cases of oropharynx cancer is an interesting alternative to chemoradiation, and in advanced disease a facultative but essential part of multimodal therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18560950     DOI: 10.1007/s10354-008-0529-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  30 in total

1.  Influence of bone invasion and extent of mandibular resection on local control of cancers of the oral cavity and oropharynx.

Authors:  C J O'Brien; J R Adams; E B McNeil; P Taylor; P Laniewski; A Clifford; G D Parker
Journal:  Int J Oral Maxillofac Surg       Date:  2003-10       Impact factor: 2.789

2.  Impact of socioeconomic status on the diagnosis to treatment interval in Waldeyer's ring carcinoma.

Authors:  Karsten Munck; Mir Jafer Ali; Andrew H Murr; Andrew N Goldberg
Journal:  Laryngoscope       Date:  2005-07       Impact factor: 3.325

3.  Carcinoma of the tonsillar fossa. An update.

Authors:  J D Spiro; R H Spiro
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1989-10

4.  Mandibular "swing" approach for oral and oropharyngeal tumors.

Authors:  R H Spiro; F P Gerold; E W Strong
Journal:  Head Neck Surg       Date:  1981 May-Jun

5.  Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer.

Authors:  Douglas K Frank; Kenneth S Hu; Bruce E Culliney; Mark S Persky; Moses Nussbaum; Stimson P Schantz; Stephen C Malamud; Roy A Holliday; Azita S Khorsandi; Roy B Sessions; Louis B Harrison
Journal:  Laryngoscope       Date:  2005-06       Impact factor: 3.325

6.  Transoral laser surgery for pharyngeal and pharyngolaryngeal carcinomas.

Authors:  Jürg Kutter; Florian Lang; Philippe Monnier; Philippe Pasche
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-02

7.  Surgery after organ preservation therapy. Analysis of wound complications.

Authors:  A M Sassler; R M Esclamado; G T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-02

8.  Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue.

Authors:  Wolfgang Steiner; Oliver Fierek; Petra Ambrosch; Christian P Hommerich; Martina Kron
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-01

9.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).

Authors:  C Domenge; C Hill; J L Lefebvre; D De Raucourt; B Rhein; P Wibault; P Marandas; B Coche-Dequeant; M Stromboni-Luboinski; H Sancho-Garnier; B Luboinski
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

10.  Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynx.

Authors:  Guy J Petruzzelli; Fanchon K Knight; Darl Vandevender; Joseph I Clark; Bahman Emami
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.